Have vaccines for Mpox been developed?<\/p>\n\n\n\n
Yes, vaccines for Mpox have been developed. The European Union, United States, Canada, and other countries approved the use of the MVA-BN vaccine in 2022 during the first declared global health emergency for Mpox.<\/p>\n\n\n\n
How do these vaccines work?<\/p>\n\n\n\n
Vaccines to protect against Mpox exist, but none specifically target the monkeypox virus. This is possible because the monkeypox virus belongs to the Orthopoxvirus genus, which includes viruses like variola (smallpox), cowpox, and vaccinia. These viruses share significant genetic similarities, allowing vaccines developed for one to protect against others through a phenomenon called cross-reactivity. This means that antibodies produced against one virus can also protect against another due to their structural similarities.<\/p>\n\n\n\n
Effectiveness of Smallpox Vaccination Against Mpox<\/p>\n\n\n\n
While previous smallpox vaccination offers some protection against Mpox, it is not a guarantee. Smallpox was eradicated in 1980, and mass immunization stopped, leading to lower antibody levels against monkeypox in people born after this period. Studies suggest the smallpox vaccine is about 85% effective in preventing Mpox, and those vaccinated tend to have milder cases.<\/p>\n\n\n\n
Current Vaccines<\/p>\n\n\n\n
As of August 2024, the MVA-BN vaccine (Modified Vaccinia Ankara-Bavarian Nordic) is the only vaccine approved for use against Mpox in the EU\/EEA, UK, US, Switzerland, and Canada. Developed in the 1950s and \u201860s in Germany and produced by Bavarian Nordic since 2010, it is administered in two doses, 28 days apart. Other vaccines include Japan\u2019s LC16 and Russia\u2019s OrthopoxVac, approved during the 2022 outbreak, and ACAM2000, recommended in the US and Australia for those at risk of Orthopoxvirus infections.<\/p>\n\n\n\n
Vaccines in Development<\/p>\n\n\n\n
New vaccines are in development, including the mRNA vaccine BNT166, which specifically targets antigens on the monkeypox virus and is currently under clinical evaluation.<\/p>\n\n\n\n
This comprehensive approach to vaccination highlights the ongoing efforts to protect against Mpox and other Orthopoxvirus infections.<\/p>\n\n\n\n
The mRNA vaccine BNT166 is a promising development in the fight against Mpox. Here are some key details:<\/p>\n\n\n\n
Overview
BNT166 is a multivalent mRNA vaccine designed to protect against the monkeypox virus (MPXV) and other Orthopoxviruses. It was developed by BioNTech, the same company known for its COVID-19 mRNA vaccines12.<\/p>\n\n\n\n
How It Works
The vaccine encodes multiple antigens from the monkeypox virus, specifically targeting proteins A35, B6, M1, and H3. These proteins are found in the two infectious forms of the virus: extracellular virions (EVs) and mature virions (MVs). By targeting these proteins, the vaccine aims to elicit strong antibody and T cell responses, providing broad protection against different strains of the virus12.<\/p>\n\n\n\n
Preclinical Studies
In preclinical studies, BNT166 has shown promising results. It has been tested in mice and non-human primates (NHPs), demonstrating robust immune responses and protection against both clade I and clade IIb MPXV. The vaccine was able to protect mice from weight loss and death when challenged with the virus, and it significantly reduced viral loads in the lungs12.<\/p>\n\n\n\n
Clinical Trials
BNT166 is currently undergoing clinical evaluation to assess its safety and immunogenicity in humans. The ongoing Phase 1\/2 clinical trial aims to determine the optimal dosage and further evaluate the vaccine\u2019s effectiveness3.<\/p>\n\n\n\n
Future Prospects
If successful, BNT166 could become a crucial tool in preventing Mpox and potentially other Orthopoxvirus infections. Its development highlights the adaptability of mRNA technology in addressing emerging infectious diseases12.<\/p>\n\n\n\n
Feel free to ask if you have more questions about this vaccine or anything else!<\/p>\n","protected":false},"excerpt":{"rendered":"
Have vaccines for Mpox been developed? Yes, vaccines for Mpox have been developed. The European…<\/p>\n","protected":false},"author":2,"featured_media":1275,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/posts\/1272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1272"}],"version-history":[{"count":1,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/posts\/1272\/revisions"}],"predecessor-version":[{"id":1276,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/posts\/1272\/revisions\/1276"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=\/wp\/v2\/media\/1275"}],"wp:attachment":[{"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thestatemonitor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}